In the third quarter, INNOVENT BIO achieved total product revenue exceeding 3.3 billion yuan, maintaining a strong year-on-year growth of approximately 40%

INNOVENT BIO achieved total product revenue exceeding 3.3 billion yuan in the third quarter of 2025, a year-on-year increase of approximately 40%. The company maintains a leading position in the field of cancer treatment, with major products such as DABOSHU® showing steady growth, and the proportion of revenue from innovative products increasing. At the same time, comprehensive product lines such as XINERMEI® and XINBILE® have shown significant market access and marketing effectiveness, driving revenue growth. The company has received approval for 16 products and is committed to global innovation and sustainable growth, aiming to become a world-class biopharmaceutical company